Jimmy Vanhove
Amministratore Delegato presso Viralgen Vector Core SL
Posizioni attive di Jimmy Vanhove
Società | Posizione | Inizio | Fine |
---|---|---|---|
Viralgen Vector Core SL
Viralgen Vector Core SL BiotechnologyHealth Technology Viralgen Vector Core SL is a contract development and manufacturing organization (CDMO) that produces AAV gene therapy treatments for pharmaceutical and biotech companies. The company was founded in 2017 by Javier García Cogorro and is based in Donostia-San Sebastian, Spain. Viralgen offers the Pro10™ based suspension manufacturing platform, which increases scalability, performance, and yield of AAV therapies. The Spanish company's clinical facilities have four CGMP manufacturing suites, with 250-liter and 500-liter bioreactors. In 2020, Viralgen expanded within the scientific park by constructing a new building for large-scale commercial manufacturing. The new state-of-the-art space includes three additional CGMP suites with a manufacturing capacity of >2,000 liters each, as well as a suite dedicated to fully automated fill and finish operations. The new facility has received the CGMP certification by the Spanish Agency for Medicines and Medical Devices (AEMPS) as part of the EMA network. The CEO is Jimmy Vanhove. | Amministratore Delegato | 01/01/2023 | - |
Corporate Officer/Principal | - | 01/01/2023 |
Storia della carriera di Jimmy Vanhove
Formazione di Jimmy Vanhove
Katholieke Universiteit Leuven | Graduate Degree |
Vlerick Leuven Gent Management School | Graduate Degree |
Statistiche
Distribuzione geografica
Belgio | 3 |
Spagna | 2 |
Posizioni
Graduate Degree | 2 |
Chief Executive Officer | 1 |
Corporate Officer/Principal | 1 |
Settori
Consumer Services | 3 |
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Viralgen Vector Core SL
Viralgen Vector Core SL BiotechnologyHealth Technology Viralgen Vector Core SL is a contract development and manufacturing organization (CDMO) that produces AAV gene therapy treatments for pharmaceutical and biotech companies. The company was founded in 2017 by Javier García Cogorro and is based in Donostia-San Sebastian, Spain. Viralgen offers the Pro10™ based suspension manufacturing platform, which increases scalability, performance, and yield of AAV therapies. The Spanish company's clinical facilities have four CGMP manufacturing suites, with 250-liter and 500-liter bioreactors. In 2020, Viralgen expanded within the scientific park by constructing a new building for large-scale commercial manufacturing. The new state-of-the-art space includes three additional CGMP suites with a manufacturing capacity of >2,000 liters each, as well as a suite dedicated to fully automated fill and finish operations. The new facility has received the CGMP certification by the Spanish Agency for Medicines and Medical Devices (AEMPS) as part of the EMA network. The CEO is Jimmy Vanhove. | Health Technology |
- Borsa valori
- Insiders
- Jimmy Vanhove
- Esperienza